Gretchen N. Batzel

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

David Olmos, Sophie Postel‐Vinay, L Rhoda Molife et al. · The Lancet Oncology · 2009 · 339 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +16

Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors

Paul Haluska, Heather M. Shaw, Gretchen N. Batzel et al. · Clinical Cancer Research · 2007 · 268 citations

Pharmacy, Oncology, Pharmacology +15

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

Paul Haluska, F. Worden, David Olmos et al. · Cancer Chemotherapy and Pharmacology · 2009 · 191 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +11

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

Joleen M. Hubbard, Charles Erlichman, David O. Toft et al. · Investigational New Drugs · 2010 · 37 citations

Medicine, Oncology, Pharmacology +10

Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors

Paul Haluska, Heather Shaw, Gretchen N. Batzel et al. · Journal of Clinical Oncology · 2007 · 22 citations

Medicine, Oncology, Pharmacology +17